ClinicalTrials.gg
CompletedNCT06714955Updated Sep 22, 2025

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

A Phase 1 interventional study of Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week. and Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week. in Non-diabetic Overweight or Obese, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.

Enrollment
9th of 10
30 · median 78
Started
2024
with 2 others
Phase 1
6 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
8 of 10
BrightGene Bio-Medical Technology Co., Ltd.

Among the 10 studies testing BGM0504 in Obesity, this one is the 9th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →

Where they have run

About BGM0504

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing BGM0504 in Obesity as a file.
02

Study summary

This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC) administrations in non-diabetic overweight or obese adult subjects.

03

Conditions studied

  • Non-diabetic Overweight or Obese

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) meeting one of the following requirements:

    1. Between ≥ 30.0 kg/m2 and ≤ 40.0 kg/m2 (obese); OR
    2. Between ≥ 27.0 kg/m2 and \< 30.0 kg/m2 (overweight) with at least 1 of the following: 1) One or more of prediabetes (impaired fasting plasma glucose and/or abnormal glucose tolerance), grade 1 hypertension, simple fatty liver or dyslipidemia; 2) Weight-bearing joint pain; 3) Obesity causing dyspnea or obstructive sleep apnea syndrome
  • Have a stable body weight (\<5% self-reported change during the previous 8 weeks) before screening
  • Capable of understanding the written document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.

Exclusion criteria

Exclusion Criteria:

  • Have allergic predisposition (allergic to 3 or more foods or drugs), or are allergic to glucagon-like peptide-1 (GLP-1) receptor agonists, or suffer from severe allergic diseases (asthma, urticaria, eczematous dermatitis).
  • Have received GLP-1 receptor agonists or similar drugs containing the same target within 12 weeks before screening.
  • Have received drugs that have an impact on body weight within 12 weeks before screening.
  • Surgical treatment for obesity.
  • Known type I/II diabetes.
  • History of acute or chronic pancreatitis or pancreatic injury.
  • History of drug abuse or alcoholism at screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

    Drug: BGM0504 Administered SC

    Drug: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

  • Experimental
    Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.

    Drug: BGM0504 Administered SC

    Drug: Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.

  • Placebo comparator
    Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.

    Drug: Placebo Administered SC

    Drug: Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.

Interventions

  • DrugExperimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

    Drug: BGM0504 Administered SC

  • Drug: BGM0504 Administered SC

  • DrugPlacebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.

    Drug: Placebo Administered SC

06

What researchers measure

Primary outcomes

  1. Number of treatment adverse events

    The relationship of each adverse event tothe investigational product was assessed by the investigator

    Time frame: 10 weeks

Secondary outcomes

  1. Pharmacokinetic endpoint: Concentration of BGM0504 in plasma

    Time frame: 10 weeks

  2. Change in fasting weight at week 10

    Time frame: 10 weeks

07

Study locations

1 site
  • Pharmaron CPC, Inc
    Baltimore, Maryland 21201, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jan 2025, 3 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 4, 2024
StartActual
Oct 21, 2024
Primary completionActual
Jan 21, 2025
CompletionActual
Mar 3, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06714955
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Oct 21, 2024
Primary completion
Jan 21, 2025
Completion
Mar 3, 2025
Last update
Sep 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion